by Sermonix Pharmaceuticals | Jun 26, 2023 | News
Sermonix used the Tempus TIME Trial® Network to enroll 45% of its ELAINE-2 patients The company is again partnering with Tempus to enroll patients in its Phase 3 ELAINE-3 study COLUMBUS, Ohio, June 26, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a...
by Sermonix Pharmaceuticals | Jun 5, 2023 | News
CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today broadly shared a poster...
by Sermonix Pharmaceuticals | May 26, 2023 | News
COLUMBUS, Ohio, May 25, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today shared...
by Sermonix Pharmaceuticals | Mar 15, 2023 | News
Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS) One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational lasofoxifene versus fulvestrant Second abstract addressed patients...
by Sermonix Pharmaceuticals | Mar 9, 2023 | News
Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS) One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational lasofoxifene versus fulvestrant Second abstract addressed patients...
by Sermonix Pharmaceuticals | Mar 6, 2023 | News
Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS) One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational lasofoxifene versus fulvestrant Second abstract addressed patients...
Recent Comments